Articles

The drug, known as XIPERE in the US, is used to treat uvietic macular edema and goes by the name Arcatus when licensed by Clearside Biomedical’s partner in China, Arctic Vision.

The 2023 41st annual meeting of the American Society of Retina Specialists (ASRS) will run from Thursday, July 27 to Tuesday, August 1 in Seattle, a city filled with sightseeing, museums, and great food to explore.

The London-based company will use regenerative medicine to fight ocular disease.

Investigators set out to evaluate how well an AI system works when integrated into a handheld smartphone-based retinal camera to screen patients for DR using 1 retinal image in each eye.

Hundreds of previously-unknown genes could be vital for early detection and treatment.

The use of topical insulin eye drops led to a successful resolution of PEDs in 9 of 11 cases in the study.

This trial is testing tinlarebant, a novel oral therapy which is intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA).

Orbis International physician spotlights the latest trends for cataract surgery training.

The open-access tool is the official registry partner of the European Glaucoma Society.

The fellowship is a one-year program that will provide comprehensive training to residency graduates in the latest advancements in ophthalmology, including diagnostic and therapeutic techniques, surgical procedures and clinical research.

The company has entered a definitive agreement with Novartis to acquire Xiidra (liftegrast ophthalmic solution 5%), representing a significant opportunity for growth in prescription dry eye.

The company seeks to replicate European success of the ELIOS procedure in the US market.

The pharmaceutical company will present study results at the World Glaucoma Congress.

Horizon Therapeutics announced the Brazilian Health Regulatory Agency (ANVISA) has approved TEPEZZA as the first and only medicine approved in Brazil for treatment of thyroid eye disease.

The company announced the Complete Response Letter from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”

The live streamed event will cover topics including DME, CME, AON and more.

According to researchers, the new imaging approach reveals changes in retinal microcirculation may indicate brain diseases that involve reduced blood flow.

The two winners were awarded a €60,000 prize for their work to treat degenerative retinal disease.

Researchers totaled the societal and healthcare costs of inherited retinal diseases.

AG-80208 is a novel, first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop to treat the inflammation linked with DED.

The lenses are designed to correct and prevent myopia in children ages 6 to 14.

Did you miss the 2023 European Society of Ophthalmology congress? Don't worry – you can catch up with our video coverage.

Artificial intelligence (AI) is going to be highly instrumental in patient care in all medical specialties and will be highly relevant in eye care.

Jorge L. Alió, MD, PhD, FEBOphth, shared his pearls situations in which a patient presents with a cataract and corneal opacity at the European Society of Ophthalmology Conference, Prague.

Paracentral acute middle maculopathy can develop after excessive intake of caffeine and alcohol according to Obadah Moushmoush, MD.

Omnigen® may be an alternative treatment option for patients with a persistent corneal epithelial defect. The product provides a convenient and effective treatment that can be administered in an outpatient setting.

Scientists hope to develop novel AI solutions for the prediction of DPN using corneal OCT images.

The new company debuted with £96 million in funding to target retinal diseases.

The EACCME accreditation is renewed through 2025.

The trial is evaluating Oxurion’s novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for DME patients who respond suboptimally to anti-VEGF therapy.